Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The cancer-specific lncRNA LISR customizes ribosomes to suppress antitumour immunity

ABSTRACT: The cancer-specific lncRNA LISR customizes ribosomes to suppress antitumour immunity

PROVIDER: PRJNA918368 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The cancer-specific lncRNA LISR customizes ribosomes to suppress antitumour immunity

Project description:We report the changes in translatome of a melanoma line upon knock down of LISR

2025-09-10 | GSE222143 | GEO

Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy

Project description:Current chemotherapy or immunotherapy regimens for pancreatic cancer are limited. Although minimally invasive irreversible electroporation (IRE) ablation is a promising option for unresectable pancreatic cancers, the typical immunosuppressive tumour microenvironment promotes immune evasion and rapid tumour recurrence. Thus, triggering efficient amplification of endogenous adaptive antitumour immunity is critical for improving immunotherapy after ablation therapy. Here, we developed a hydrogel microsphere vaccine as an immune amplifier for post-ablation cancer immunotherapy. The vaccine acts as a general immune amplifier to trigger a rocket-like amplification of the cDC1-mediated antigen cross-presentation cascade, resulting in dramatic amplification of the antitumour immunity of endogenous CD8+ T cells. We also showed that the hydrogel microsphere vaccine promoted the transformation of pancreatic cancer from "cold" to "hot" tumours in a safe and efficient manner, significantly increased the survival of mice bearing orthotopic pancreatic tumours, and induced strong systemic antitumour immunity, which inhibited the growth of distant metastases.

2023-05-22 | GSE215417 | GEO

PROCR diminishes the efficacy of radiation by impairing T cell-mediated antitumour immunity

Project description:We found that PROCR promotes IL-6 secretion, which is magnified after radiation, leading to inhibition of antitumour immunity. Next, we investigated the mechanism by which PROCR upregulated IL-6. To this end, we performed RNA sequencing on irradiated HONE1 cells with or without PROCR knockout.

2025-05-29 | GSE282897 | GEO

Denosumab Enhances antitumour Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

Project description:Denosumab Enhances antitumour Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

| PRJNA1118819 | ENA

The generation of cancer-specific ribosomes by the lncRNA LISR suppresses melanoma anti-tumour immunity

Project description:Gains of chromosome 12p11.21, encoding for the cancer-specific lncRNA LISR, correlate with poor survival in the PanCancer Atlas. In melanoma, LISR is highly expressed by patients resistant to immunotherapy and it contributes to the generation of drug-tolerant persister cells by activating an immune suppressive translational program affecting the synthesis of PD-L1 and of the glycocalyx. Interestingly, the use of glycans to evade the immune system is a characteristic of the sperm. Accordingly, a defective glycocalyx assembly during spermatogenesis causes infertility. Here we show that LISR affects the core ribosome composition and recruits Deleted in AZoospermia Associated Protein 1 (DAZAP1) to regulate an immune suppressive translational program that includes PD-L1 and several glycosylases. Consequently, down-regulation of LISR leads to robust anti-tumour immune responses and re-sensitizes to immune checkpoint blockade. Our study reveals the contribution of lncRNAs to the generation of cancer-specific ribosomes and identifies an RNA-based cancer-specific strategy to overcome intrinsic resistance to immune checkpoint +blockade.

2025-09-17 | PXD046528 | Pride

PROCR diminishes the efficacy of radiation by impairing T cell-mediated antitumour immunity

Project description:PROCR diminishes the efficacy of radiation by impairing T cell-mediated antitumour immunity

| PRJNA1190963 | ENA

Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

Project description:Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

| PRJNA1066759 | ENA

Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

Project description:Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

| PRJNA1066825 | ENA

Antitumour activity of Micromeria fruticosa on Cancer Cell Lines

Project description:Investigate the mechanistic pathway for the antitumour activity of M. fruticosa on different cancer cell lines

2019-06-28 | GSE116540 | GEO

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity

Project description:Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity

| PRJNA1001942 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data